Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 1 art units • 3 examiners • 0 of 5 (0%) have an AI response strategy ready
Scion Holdings LLC has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners but remain within 1 art unit, indicating examiner variation within a consistent technical examination setting.
WITHERSPOON, SIKARL A is the busiest examiner, with 2 pending actions. The docket therefore warrants coordination across matters while preserving attention to examiner-specific issues.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WITHERSPOON, SIKARL A | 2 | 86.3% | -20.1% |
| BAHTA, MEDHANIT W | 2 | 80.6% | +27.8% |
| KELLY-O'NEILL, YOLANDA LYNNETTE | 1 | 31.8% | +23.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17553752 | Branched Products | BAHTA, MEDHANIT W | 100d overdue |
| 17331371 | Branched Compounds | BAHTA, MEDHANIT W | 27d |
| 18198809 | Branched Aldehyde Production | WITHERSPOON, SIKARL A | 83d |
| 18562959 | Branched Technologies | WITHERSPOON, SIKARL A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17553752 | Branched Products | BAHTA, MEDHANIT W | 100d overdue |
| 18266039 | Branching Technology | KELLY-O'NEILL, YOLANDA LYNNETTE | 67d overdue |
| 17331371 | Branched Compounds | BAHTA, MEDHANIT W | 27d |
| Art Unit | Apps |
|---|---|
| 1692 | 5 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562959 | Branched Technologies | WITHERSPOON, SIKARL A | 1692 | §103Other | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18266039 | Branching Technology | KELLY-O'NEILL, YOLANDA LYNNETTE | 1692 | §102§103DP | Final Rejection | 67d overdue | Pending | Jun 08, 2023 |
| 18198809 | Branched Aldehyde Production | WITHERSPOON, SIKARL A | 1692 | DP | Non-Final OA | 83d | Pending | May 17, 2023 |
| 17553752 | Branched Products | BAHTA, MEDHANIT W | 1692 | §102§103DP | Non-Final OA | 100d overdue | Pending | Dec 16, 2021 |
| 17331371 | Branched Compounds | BAHTA, MEDHANIT W | 1692 | §103Other | Non-Final OA | 27d | Pending | May 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialScion Holdings LLC has 5 pending office actions as of October 2026, spread across 1 art units and 3 examiners.
Sikarl A Witherspoon has the most, with 2 of Scion Holdings LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
